The Manufacturers Life Insurance Company Acquires Shares of 11,247 ChromaDex Co. (NASDAQ:CDXC)

The Manufacturers Life Insurance Company purchased a new stake in ChromaDex Co. (NASDAQ:CDXC) in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund purchased 11,247 shares of the company’s stock, valued at approximately $31,000.

Other hedge funds have also recently made changes to their positions in the company. Miracle Mile Advisors LLC acquired a new position in ChromaDex during the 2nd quarter valued at approximately $27,000. Merriman Wealth Management LLC acquired a new stake in ChromaDex during the 2nd quarter worth about $32,000. Lazard Asset Management LLC purchased a new position in shares of ChromaDex during the 1st quarter valued at about $43,000. SG Americas Securities LLC purchased a new position in ChromaDex during the first quarter valued at approximately $54,000. Finally, Marshall Wace LLP acquired a new position in ChromaDex in the second quarter valued at approximately $56,000. 15.41% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In other news, Director Kristin Patrick sold 23,000 shares of ChromaDex stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $3.57, for a total value of $82,110.00. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. 9.64% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Separately, HC Wainwright reaffirmed a “buy” rating and set a $6.00 price objective on shares of ChromaDex in a research note on Friday, August 9th.

ChromaDex Trading Down 1.1 %

Shares of CDXC opened at $3.46 on Tuesday. ChromaDex Co. has a 12 month low of $1.25 and a 12 month high of $4.65. The firm has a market cap of $261.36 million, a P/E ratio of -69.20 and a beta of 1.86. The stock’s 50 day moving average is $3.44 and its two-hundred day moving average is $3.24.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.